More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings...
More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings climbed 65% on higher demand for its clinical R&D services and data analysis. Service revenue rose 27% to $422.1M, with newly-acquired Liquent contributing $400K in the quarter. Backlog at the end of December was approximately $4.54B, up 21.4% Y/Y. It also raises FY guidance, now expecting to earn $1.48 to $1.56 per share, with consolidated service revenue between $1.695B and $1.710B. Shares +3.4% AH.
Check out Seeking Alpha’s new Earnings Center »
From other sites
at Zacks.com (Mar 27, 2015)
at Nasdaq.com (Jan 26, 2015)
at CNBC.com (Dec 24, 2014)
at Benzinga.com (Dec 19, 2014)
at CNBC.com (Oct 30, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs